ASND Ascendis Pharma A/S

126.55
+0.19  (+0%)
Previous Close 126.36
Open 126.5
Price To Book 18.95
Market Cap 5925601118
Shares 46,824,189
Volume 240,303
Short Ratio
Av. Daily Volume 287,574

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data released March 4, 2019. Primary endpoint met. Phase 3 fliGHt trial detailed data due June 26, 2019.
TransCon hGH
Growth hormone deficiency in children
Phase 2 top-line data due 4Q 2019.
TransCon
Hypoparathyroidism
Phase 2 trial to be initiated 2Q 2019.
TransCon CNP
Achondroplasia

Latest News

  1. Ascendis Pharma A/S Announces Preliminary Data from Single Arm Phase 3 fliGHt Trial Demonstrated TransCon™ hGH was Safe and Well-Tolerated in Pediatric Subjects Previously Treated with Daily Growth Hormone
  2. Ascendis Pharma A/S Announces First Quarter 2019 Financial Results and Business Update Conference Call on May 30
  3. Ascendis Pharma A/S Announces Participation in the Bank of America Merrill Lynch 2019 Healthcare Conference
  4. Wyndham Hotels & Resorts, Inc. (WH): 2019 Sohn Conference New York Recap
  5. What You Must Know About Ascendis Pharma A/S's (NASDAQ:ASND) Financial Health
  6. Did Hedge Funds Drop The Ball On Ascendis Pharma A/S (ASND) ?
  7. Glenview Capital Management’s Stock Pitches At 2018 Sohn Conference
  8. Ascendis Pharma A/S Announces Presentations Related to Rare Disease Endocrinology Pipeline at Upcoming Medical Conferences
  9. Joseph Jolson’s Harvest Capital Strategies’ Return, AUM, and Holdings
  10. Best Stock Pick From The 2018 Sohn Conference (Part II)
  11. Edited Transcript of ASND earnings conference call or presentation 3-Apr-19 8:30pm GMT
  12. What Happened With Light Street’s Glen Kacher’s Best Idea at 2018 Sohn Conference?
  13. Mangrove Partners’ Nathaniel August’s Best Idea At 2018 Sohn Conference
  14. Sarissa Capital Management Hires New President
  15. Ascendis Pharma A/S (ASND) Q4 2018 Earnings Conference Call Transcript
  16. Ascendis Pharma A/S Reports Full Year 2018 Financial Results
  17. Ascendis Pharma A/S Sponsored ADR to Host Earnings Call
  18. Ascendis Pharma A/S Announces Year-End 2018 Financial Results and Business Update Conference Call on April 3
  19. Ascendis Pivotal Growth Hormone Deficiency Study Data Positive
  20. Ascendis Pharma Announces Results of Study at ENDO 2019 Evaluating Impact of Hypoparathyroidism on Patient Quality-of-Life